SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations, tell me about this news in (https://www.manilatimes.net/2026/09/23/tmt-newswire/globenewswire/scisparc-subsidiary-neurothera-highlights-enhancement-of-us-patent-portfolio-through-collaboration-with-clearmind-covering-lsd-ketamine-and-ibogaine-combinations/2431308)

On September 23, 2026, SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., expanded its U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc.

• Published Patent Applications: Three U.S. patent applications were published covering proprietary combinations of N-acylethanolaminesspecifically palmitoylethanolamide (PEA), NeuroThera’s proprietary technologywith three psychoactive compounds:

  • Lysergic acid diethylamide (LSD)

  • Ketamine

  • Ibogaine

• Target Therapeutic Applications: The patent applications focus on potential therapeutic treatments for a variety of conditions, notably:

  • Mental health disorders (such as major depression and post-traumatic stress disorder / PTSD)

  • Substance use disorders

  • Pain management

• Building on Existing IP: These new filings expand upon prior intellectual property created through the collaboration between NeuroThera and Clearmind, which previously included a U.S. patent application for combining MDMA with N-acylethanolamines to treat PTSD, anxiety, and eating disorders.

• Strategic Goal: The collaboration aims to leverage PEA’s synergistic properties alongside psychedelic and psychoactive compounds to develop safer, more effective treatments for widespread and growing central nervous system and mental health disorders.